Literature DB >> 6706729

Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.

B S Hilaris, D Nori, E Kwong, G J Kutcher, N Martini.   

Abstract

Forty-one patients with diffuse, pleural mesothelioma limited to one hemi-thorax underwent a thoracotomy at Memorial Sloan-Kettering Cancer Center from January 1976 to July 1982. Treatment at thoracotomy consisted of as complete a parietal pleurectomy as was possible to remove the bulk of the tumor. Measurable gross residual disease was treated whenever feasible, with permanent 125I implantation; residual diffuse disease was treated by a temporary 192Ir implantation or by postoperative instillation of 32P. External radiation therapy was given 4-6 weeks postoperatively to the involved hemi-thorax, shielding the lung and utilizing a combination of electron and a photon beam. A dose of 4500 rad in 4.5 weeks was given to the pleural surface by the mixed beam. There was no postoperative mortality in this group of 41 patients. Complications developed in 6 patients (15%). The median survival was 21 months; the one year survival was 65% and the two year survival was 40%. The median disease-free survival was 11 months and the one and two year disease-free survival 44 and 13% respectively. This study suggests that the combination of pleurectomy, intraoperative brachytherapy and postoperative external radiation increased the local control of the tumor and prolonged the survival.

Entities:  

Mesh:

Year:  1984        PMID: 6706729     DOI: 10.1016/0360-3016(84)90050-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

Review 1.  What is the role of radiotherapy in malignant pleural mesothelioma?

Authors:  Allan Price
Journal:  Oncologist       Date:  2011-02-23

2.  FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.

Authors:  Victor H Gerbaudo; Marcelo Mamede; Beatrice Trotman-Dickenson; Hiroto Hatabu; David J Sugarbaker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

3.  Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication.

Authors:  William F Sensakovic; Samuel G Armato; Adam Starkey; Hedy L Kindler; Wickii T Vigneswaran
Journal:  Acad Radiol       Date:  2010-12-10       Impact factor: 3.173

4.  Surgical treatment of malignant pleural mesothelioma.

Authors:  Andrew J Kaufman; Raja M Flores
Journal:  Curr Treat Options Oncol       Date:  2011-06

Review 5.  Cerebral metastases in pleural mesothelioma: case report and review of the literature.

Authors:  M Wroński; M Burt
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

6.  Intrapleural photodynamic therapy: results of a phase I trial.

Authors:  H I Pass; T F DeLaney; Z Tochner; P E Smith; B K Temeck; H W Pogrebniak; K C Kranda; A Russo; W S Friauf; J W Cole
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

7.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 8.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

Authors:  S Tomek; S Emri; K Krejcy; C Manegold
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

9.  Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy.

Authors:  Khosrow Javedan; Craig W Stevens; Kenneth M Forster
Journal:  J Appl Clin Med Phys       Date:  2008-10-29       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.